HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for Cardiol Therapeutics, maintaining a price target of $9. This suggests confidence in the company's future performance.
October 24, 2024 | 11:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Cardiol Therapeutics, maintaining a price target of $9. This suggests confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $9 price target by HC Wainwright & Co. indicates a positive outlook on Cardiol Therapeutics' stock. This can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100